Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP‑2 expression

Wang,Zhenyu; You,Dingyun; Lu,Minnan; He,Yuefeng; Yan,Shan

doi:10.3892/ol.2017.5622

Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP‑2 expression

Authors:
- Zhenyu Wang
- Dingyun You
- Minnan Lu
- Yuefeng He
- Shan Yan
View Affiliations

Affiliations: Biomedical Engineering Research Center, Kunming Medical University, Yunnan, Kunming 650500, P.R. China, Department of Science and Technology, Kunming Medical University, Yunnan, Kunming 650500, P.R. China, Experimental Center for Medical Science Research, Kunming Medical University, Yunnan, Kunming 650500, P.R. China, School of Public Health, Kunming Medical University, Yunnan, Kunming 650500, P.R. China, Institute of Molecular and Clinical Medicine, Kunming Medical University, Yunnan, Kunming 650500, P.R. China
Published online on: January 18, 2017 https://doi.org/10.3892/ol.2017.5622
Pages: 1660-1664
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A form of microcirculation called vasculogenic mimicry (VM), which constitutes a novel approach for tumor blood supply in certain highly aggressive malignant tumors, was recently reported to contribute to tumor metastasis and poor prognosis in melanoma patients. Development of strategies to target tumor VM may be significant to reduce the recurrence and metastasis of melanoma. Norcantharidin (NCTD) has been shown to inhibit tumor growth and VM of human gallbladder carcinomas. Besides, NCTD could induce melanoma cell apoptosis. However, whether NCTD can inhibit the growth and VM formation of melanoma has not been evaluated. The present study aims to investigate the anti‑VM activity of NCTD as a VM inhibitor for melanoma and its potential mechanisms. The anti‑VM activity of NCTD was determined in human melanoma A375 cells and xenografts in vitro and in vivo. The findings indicate that NCTD inhibits tumor growth and VM formation of melanoma both in vitro and in vivo by suppressing matrix metalloproteinase‑2 expression. The results suggest that NCTD is a potential therapeutic agent targeting VM in melanoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Neitzel LT, Neitzel CD, Magee KL and Malafa MP: Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol. 6:70–74. 1999. View Article : Google Scholar : PubMed/NCBI
3	Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
4	Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK and Folberg R: Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 7:473–477. 2001.PubMed/NCBI
5	Liu WB, Xu GL, Jia WD, Li JS, Ma JL, Chen K, Wang ZH, Ge YS, Ren WH, Yu JH, et al: Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol. 28:(Suppl 1). S228–S238. 2011. View Article : Google Scholar : PubMed/NCBI
6	Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 99:821–828. 2002. View Article : Google Scholar : PubMed/NCBI
7	Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, Folberg R and Hendrix MJ: Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis. 19:233–246. 2002. View Article : Google Scholar : PubMed/NCBI
8	van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW and Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
9	Rice C and Huang LE: From antiangiogenesis to hypoxia: Current research and future directions. Cancer Manag Res. 3:9–16. 2010.PubMed/NCBI
10	Sun M, Han J, Duan J, Cui Y, Wang T, Zhang W, Liu W, Hong J, Yao M, Xiong S and Yan X: Novel antitumor activities of Kushen flavonoids in vitro and in vivo. Phytother Res. 21:269–277. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yeh CB, Hsieh MJ, Hsieh YH, Chien MH, Chiou HL and Yang SF: Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity. PLoS One. 7:e310552012. View Article : Google Scholar : PubMed/NCBI
12	Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY, Zhao ZM, Lu XS and Fan YZ: Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway. BMC Cancer. 14:1932014. View Article : Google Scholar : PubMed/NCBI
13	An WW, Wang MW, Tashiro S, Onodera S and Ikejima T: Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways. J Korean Med Sci. 19:560–566. 2004. View Article : Google Scholar : PubMed/NCBI
14	Qin Y, Zhang Q, Lee S, Zhong WL, Liu YR, Liu HJ, Zhao D, Chen S, Xiao T, Meng J, et al: Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget. 6:40667–40679. 2015.PubMed/NCBI
15	Hess AR, Seftor EA, Seftor RE and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
16	Hofmann-Wellenhof R, Woltsche-Kahr I, Smolle J and Kerl H: Clinical and histological features of poor prognosis in cutaneous metastatic melanomas. J Cutan Pathol. 23:199–204. 1996. View Article : Google Scholar : PubMed/NCBI
17	Chen HX and Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
18	Higa GM and Abraham J: Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. 9:999–1007. 2009. View Article : Google Scholar : PubMed/NCBI
19	Gille J: Antiangiogenic cancer therapies get their act together: Current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol. 15:175–186. 2006. View Article : Google Scholar : PubMed/NCBI
20	Grothey A and Galanis E: Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 6:507–518. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun W: Norcantharidin: A potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol. 40:1501–1514. 2012.PubMed/NCBI